| scholarly article | Q13442814 |
| P50 | author | Alfredo Berardelli | Q57029886 |
| P2093 | author name string | Carlo Colosimo | |
| Dorina Tiple | |||
| P2860 | cites work | Blepharospasm: a review of 264 patients | Q33631310 |
| Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins | Q33697286 | ||
| Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia | Q33877991 | ||
| Tetanus and botulinum neurotoxins: turning bad guys into good by research | Q33998410 | ||
| Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin | Q34102343 | ||
| Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. | Q34305982 | ||
| Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. | Q34560643 | ||
| Pathophysiology of dystonia: a neuronal model | Q34596357 | ||
| Botulinum toxin in movement disorders | Q34612991 | ||
| Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia | Q35463218 | ||
| What are the determinants of quality of life in people with cervical dystonia? | Q35466924 | ||
| Basic immunological aspects of botulinum toxin therapy | Q35693983 | ||
| Treatment of cervical dystonia with botulinum toxin | Q35693995 | ||
| Clinical comparability of marketed formulations of botulinum toxin | Q35694002 | ||
| Botulinum toxin in clinical practice | Q35807826 | ||
| Safety of botulinum toxin type A: a systematic review and meta-analysis | Q35841671 | ||
| Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia | Q36155676 | ||
| Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc | Q36370617 | ||
| Neurophysiological effects of botulinum toxin type A. | Q36511579 | ||
| Blepharospasm: demographic and clinical survey of 250 patients | Q72578942 | ||
| Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up | Q73276590 | ||
| Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure | Q73828849 | ||
| Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia | Q73998330 | ||
| The impact of blepharospasm and cervical dystonia on health-related quality of life and depression | Q74519545 | ||
| Botulinum toxin: chemistry, pharmacology, toxicity, and immunology | Q77594637 | ||
| Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? | Q77639720 | ||
| Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor | Q77647461 | ||
| Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis | Q78608665 | ||
| Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period | Q78609665 | ||
| Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results | Q80542328 | ||
| Health-related quality of life in blepharospasm or hemifacial spasm | Q81132708 | ||
| Autonomic cardiovascular function and baroreflex sensitivity in patients with cervical dystonia receiving treatment with botulinum toxin type A | Q81221506 | ||
| The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment | Q81366644 | ||
| Botulinum toxin type A and cervical dystonia: a seven-year follow-up | Q82282254 | ||
| Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex | Q82490625 | ||
| Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study | Q83091415 | ||
| Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia | Q83974689 | ||
| Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. | Q36934147 | ||
| Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology | Q37155202 | ||
| A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism? | Q37372753 | ||
| Do the unintended actions of botulinum toxin at distant sites have clinical implications? | Q37421112 | ||
| EFNS guidelines on diagnosis and treatment of primary dystonias | Q37756221 | ||
| Craniocervical dystonia: clinical and pathophysiological features | Q37768836 | ||
| Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm | Q39277130 | ||
| Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes | Q39300250 | ||
| Treatment of blepharospasm with botulinum neurotoxin type A: long-term results | Q39392400 | ||
| Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients | Q39444294 | ||
| Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin | Q39473584 | ||
| Botulinum A toxin effects on rat jaw muscle spindles | Q39494040 | ||
| Effectiveness of botulinum toxin therapy for essential blepharospasm | Q39536706 | ||
| Long-term results and complications of botulinum A toxin in the treatment of blepharospasm | Q39618796 | ||
| Botulinum toxin therapy, immunologic resistance, and problems with available materials | Q40944009 | ||
| Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects | Q41128504 | ||
| The clinical course of spasmodic torticollis | Q43847754 | ||
| Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia | Q44394591 | ||
| The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia | Q44427062 | ||
| Idiopathic cervical dystonia: clinical characteristics | Q44510674 | ||
| A long-term follow-up of botulinum toxin A in cervical dystonia | Q44590149 | ||
| Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia | Q46113364 | ||
| Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay | Q46211591 | ||
| Different types of botulinum toxin in humans | Q47935598 | ||
| Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs | Q47965734 | ||
| The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection | Q47997311 | ||
| Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study | Q48737398 | ||
| Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. | Q51553395 | ||
| Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients. | Q51813349 | ||
| Discussion of unique properties of botulinum toxins. | Q51820851 | ||
| Psychiatric disorders in adult-onset focal dystonia: a case-control study. | Q51856928 | ||
| Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. | Q51900325 | ||
| Effect of dystonia and botulinum toxin treatment on health-related quality of life. | Q53565994 | ||
| Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. | Q53577538 | ||
| Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. | Q53883937 | ||
| Long-term botulinum toxin efficacy, safety, and immunogenicity. | Q54782341 | ||
| Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection | Q56874673 | ||
| Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004* | Q59858877 | ||
| Botulinum A toxin injection as a treatment for blepharospasm | Q70069053 | ||
| Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles | Q71843083 | ||
| Response and immunoresistance to botulinum toxin injections | Q72059963 | ||
| Development of resistance to botulinum toxin type A in patients with torticollis | Q72476569 | ||
| P433 | issue | 4 | |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | 265-273 | |
| P577 | publication date | 2012-02-23 | |
| P1433 | published in | Neurotoxicity Research | Q15764278 |
| P1476 | title | Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review | |
| P478 | volume | 22 |
| Q43539225 | Adverse events associated with botulinum toxin injection: a multidepartment, retrospective study of 5310 treatments administered to 1819 patients. |
| Q36432831 | Botulinum toxin physiology in focal hand and cranial dystonia |
| Q92045288 | Cervical Kyphotic Deformity Worsening After Extensor Cervical Muscle Paralysis from Botulinum Toxin Injection |
| Q34881647 | Diffuse decreased gray matter in patients with idiopathic craniocervical dystonia: a voxel-based morphometry study |
| Q36667983 | Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial. |
| Q90007909 | How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study |
| Q33897459 | Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection. |
| Q50668003 | Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia. |
| Q47133621 | Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. |
| Q36807185 | Long-term efficacy and safety of botulinum toxin injections in dystonia |
| Q48083719 | Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years |
| Q38607345 | Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis |
| Q33935194 | Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm |
| Q88112412 | Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatment |
| Q33860731 | Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers |
| Q35694486 | Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A. |
| Q36171693 | Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement |
| Q58749782 | Repeated Intrastriatal Botulinum Neurotoxin-A Injection in Hemiparkinsonian Rats Increased the Beneficial Effect on Rotational Behavior |
| Q39944478 | Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial |
| Q30566734 | Treatment of dystonia. |
| Q38205381 | Update on treatments for dystonia |
Search more.